Dr. Harlan F. Weisman M.D. Chairman and Chief Executive Officer of CNDO is by far the best man to run this company.
Coronado Biosciences announced the appointment of Harlan F. Weisman, M.D., a director for the company since August 2012, as its new chairman and CEO. Dr. Weisman was most recently at Johnson and Johnson, where he held a number of leadership positions, and before that HE WAS THE HEAD OF R&D AT CENTOCOR, THE DEVELOPER OF REMICADE, WHICH WAS ACQUIRED BY JNJ.
REMICADE drug was for J&J the biggest seller once again; the anti-inflammatory Remicade (infliximab), sales of were up 18.6% to $1.23 billion in 2010 ("Primary contributors to operational sales growth were REMICADE® or infliximab")
Overall REMICADE is sold by 3 companies as follow ::
The drug: Remicade
Company: Johnson & Johnson/Merck/Mitsubishi Tanabe Pharma
Estimated worldwide sales 2012: $7.67 billion
So forget about a good guy Dr. Bobby W. Sandage, Jr. but he was UNABLE to deliver the FULL POTENTIAL od CNDO and its TSO.
Just Google " 2011 and 2012 Remicade revenues of J&J " and " Full Interview with Dr. Harlan Weisman " to better understand how excellent is Dr. Weisman.
Were you able to hear the audio from CBS for full interview of Dr Weismann dated April8.
I cannot hear or download the interview.
What exactly Dr Weismann says. Any clue about that this wil be game changer/approval timeframe/updates and so forth.
I am long and heavy into this one. Should I keep it or add more at this level?
Feedback and comment appericaited.
Also I see very few new member post on this board and also not much discussion on the board.
Hello. The answer to your question is YES I was able to download and hear the full discussion. You have to Google the following exact wording "Full Interview with Dr. Harlan Weisman". After you go in the small box and you Download it or you register it on your desk to keep it for reference. It works pretty well for my computer.
The decision to add more is your decision. For me I had already 23100 shares and I have added 6900 for a grand total of 30000. I don't say that to be smart but I really believe that TSO will be the discovery of the present century as it will change the way we see the relationship between our antibodies and the germs. We call that a "Paradym Shift" ( just Google that expression and go to Wikipedia )
Biography of Dr.Harlan F. Weisman M.D. Chairman of the Board and Chief Executive Officer at CORONADO BIOSCIENCES
Dr. Harlan F. Weisman, M.D has been the Chairman and Chief Executive Officer of Coronado Biosciences, Inc. since January 2, 2013. Dr. Weisman serves as Senior Vice President of Janssen Biotech, Inc. Dr. Weisman is the Founder and Managing Director of And-One Consulting, LLC, a firm that assists life sciences companies develop global strategies aimed at accelerating medical product development, regulatory approval and market acceptance. Dr. Weisman was Chief Science and Technology Officer for Medical Devices and Diagnostics at J&J. In that role, he was a member of the Medical Devices and Diagnostics Group Operating Committee steering the group's scientific and technical agendas, including investments in group-level technologies, and sponsoring the research and development talent agenda. Dr. Weisman was Group Chairman, Research & Development for Pharmaceuticals, where he had executive oversight of the ALZA Corporation, J&J Pharmaceutical Research and Development, and TransForm Pharmaceuticals, Inc. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. He served as Group Chairman of Johnson & Johnson. Dr. Weisman has been a Director of Coronado Biosciences, Inc. since August 2012. He serves as a Director of IntelliRad Control, Inc. Dr. Weisman served as an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine. Dr. Weisman received his B.A. in Philosophy from the University of Maryland and his M.D. from the University of Maryland School of Medicine. After his residency in Internal Medicine at Mount Sinai Hospital in New York, he did his post-graduate fellowship training in cardiovascular disease at Johns Hopkins Hospital.